Abstract Body

Non-small cell lung carcinoma (NSCLC) is increased in incidence and a leading cause of cancer death among people living with HIV (PLWH). We explored whether HIV-associated immunologic changes results in an immunoregulatory tumor microenvironment (TME) with limited tumor-specific responses among PLWH.

A tissue microarray was constructed with tumors from 18 HIV+ and 19 HIV- NSCLC patients (matched for histology, stage, year of diagnosis, age, sex and smoking status), and incubated with metal-conjugated antibodies for evaluation by imaging mass cytometry (IMC). IMC marker scores were extracted by automated cell segmentation and single-cell data was analyzed by Phenograph. In addition, whole exome sequencing was performed on tumor tissue.

HIV+ and HIV- tumors demonstrated differential distribution of tumor-infiltrating CD8+ T cell clusters defined by marker expression patterns. Two clusters were significantly elevated in HIV+ tumors (20.3% and 19.9% vs. 9.2% and 4.7% in HIV- tumors, p<0.0001 for both). The first cluster exhibited an activated effector memory phenotype (CD45RO+CD25+). The second cluster resembled a previously described effector burned-out 'Ebo' CD8+ T cell subset with co-expression of immune checkpoint and proliferation markers (PD-1+LAG-3+Ki67+). Within tumor-infiltrating CD4+ T cells, a cluster characterized by checkpoint protein expression (PD-1+ and LAG-3) was also highly represented in HIV+ cases (35.2% vs. 9.8% in HIV- cases, p<0.0001). Finally, HIV+ tumor-associated macrophages (TAM) had higher expression of immunoregulatory molecules (PD-L1, PD-L2, B7-H3, B7-H4, IDO1 and VISTA), confirmed by the expansion of three clusters comprising 58.8% of TAMs vs. 17.8% in HIV- tumors (p<0.0001). Discrimination of cells between HIV+ and HIV- TME was further confirmed by spectral graph theory. Furthermore, tumor mutational burden and neoantigen calling was higher among HIV+ tumors suggesting more antigenic tumors among PLWH.

Our study suggests that the TME of HIV+ patients is characterized by a unique immune landscape, distinct from that of HIV- patients, with evidence of expansion of immune cells with enhanced immunoregulatory phenotypes and associated with impaired anti-tumor responses. These differences may be due to long-standing viral replication and destruction of lymphoid architecture. Further studies are necessary to elucidate the impact of these findings on prognosis and response to treatment, particularly checkpoint inhibitor-based approaches.